Cutaneous leishmaniasis in a patient receiving infliximab

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 7, 2013, Pages 567-569

  Hernández Torres, Alicia ^a   García Vázquez, Elisa ^a   Frías Iniesta, José ^a   Herrero Martínez, José Antonio ^a   Gómez Gómez, Joaquín ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Cutaneous leishmaniasis; Infliximab; Leishmania; Tumour necrosis factor antagonists

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBODY; CORTICOSTEROID; DNA; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB;

ADULT; AMASTIGOTE; ARTICLE; CASE REPORT; CONSULTATION; CORTICOSTEROID THERAPY; DERMATOLOGIST; DISEASE COURSE; EAR MALFORMATION; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEISHMANIA MAJOR; MALE; MEDICAL HISTORY; OTALGIA; POLYMERASE CHAIN REACTION; PSORIASIS; SKIN BIOPSY; SKIN LEISHMANIASIS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEISHMANIASIS, CUTANEOUS; MALE; MEDITERRANEAN REGION; MIDDLE AGED; STEROIDS;

EID: 84879122461     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.752859     Document Type: Article

References (12)

1. Ready PD. L eishmaniasis emergence in Europe. E uro Surveill 2010; 15: 19505.
2. Goto H, Lindoso JA. C urrent diagnosis of cutaneous and mucocutaneous leishmaniasis. Expert Revanti Infect Ther 2010; 8: 419-33.
3. Rioux JA, L anotte G. L eishmania infantum as a cause of cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1990; 84: 898.
4. Hakimi S, R ivi è re S, D el Giudice P, D ereure J, L e Quelec A. Localized cutaneous leishmaniasis due to Leishmania infantum in a patient treated with infLiximab. Dermatology 2010; 220: 63-5.
5. Salmon-Ceron D, T ubach F, L ortholary O, C hosidow O, Bretagne S, Nicolas N, et al. Drug-specifi c risk of nontuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70: 616-23.
6. Mueller MC, F leischmann E, G runke M, S chewe S, B ogner JR, L ö scher T. Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infLiximab. Am J Trop Med Hyg 2009; 81: 52-4.
7. Fonseca SG, R omao PR, F iguereido F, M orais RH, Lima HC, FerreirAsh, et al. TNF-mediates the induction of nitric oxide synthase in macrophages but not in neutrophils in experimental cutaneous leishmaniasis. Eur J Immunol 2003; 33: 2297-306.
8. Zanger P, Kötter I, Kremsner PG, Gabrysch S. T umor necrosis alpha antagonist drugs and leishmaniasis in Europe. Clin MicrobioLinfect 2012; 18: 670-6.
9. Theodos CM, P ovinelli L, M olina R, S herry B, T itus RG. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect Immun 1991; 59: 2839-42.
10. Liew FY, P arkinson C, M illott S, S evern A, C arrier M. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis . Immunology 1990; 69: 570-3.
11. Titus RG, S herry B, C erami A. T umor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 1989; 170: 2097-104.
12. Yardley V, C roft S. A ctivity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997; 41: 752-6.